Understand the source comparison
Do Peptides Help With Sexual Performance: Receptor Mechanisms Versus Vascular Pathways Comparison
PT-141 (bremelanotide) Melanocortin MC3/MC4 Activates hypothalamic arousal circuits, increases dopamine and norepinephrine signaling FDA-approved (Phase 3 trials in women with HSDD) 45–90 minutes subcutaneous Nausea (40%), flushing, headache Most robust clinic
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PT-141 (bremelanotide)
- Melanocortin MC3/MC4
- Activates hypothalamic arousal circuits, increases dopamine and norepinephrine signaling
- FDA-approved (Phase 3 trials in women with HSDD)
- 45–90 minutes subcutaneous
- Nausea (40%), flushing, headache
- Most robust clinical evidence for desire-driven dysfunction; works centrally, not peripherally
- Kisspeptin-10
- GPR54 (kisspeptin receptor)
- Stimulates GnRH release, modulates HPG axis, enhances neural arousal processing
- Phase 2 trials (published in peer-reviewed journals)
- Within 60 minutes intravenous
- Minimal reported in trials. Headache, mild nausea
- Promising mechanism with early-stage evidence; not yet available clinically outside research protocols
- Melanotan II
- Melanocortin MC1/MC3/MC4
- Activates central arousal pathways plus peripheral melanocortin signaling in smooth muscle
- Phase 1–2 trials, not FDA-approved
- 2–6 hours subcutaneous
- Nausea (40%), skin darkening, spontaneous erections
- Effective in trials for psychogenic ED but lacks regulatory approval; available through research suppliers only
- PDE5 inhibitors (comparison)
- PDE5 enzyme in penile tissue
- Increases cGMP levels to facilitate smooth muscle relaxation and blood flow
- FDA-approved (extensive Phase 3 data)
- 30–60 minutes oral
- Headache, flushing, nasal congestion
- Gold standard for vascular-based erectile dysfunction; does not address desire or arousal deficits